Solve Fshd
Non-Profit & Charitable Organizations · 1-10 Employees
View Company Info for Free
Overview
Website
www.solvefshd.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Solve Fshd
SOLVE FSHD is a venture philanthropic organization dedicated to finding a cure for facioscapulohumeral muscular dystrophy (FSHD) by December 31, 2027. With a commitment of $100 million from the Wilson family, the organization aims to catalyze innovation and accelerate the development of novel therapies by partnering with leading academic, biotech, and biopharmaceutical organizations. Their mission is to remove barriers to research and support the global FSHD community throughout the process. SOLVE FSHD focuses on funding research and clinical trials to create a pipeline of new therapies for this rare neuromuscular disease.Explore more
Solve Fshd Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Solve Fshd your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Solve Fshd recently announced quarterly report
Check out if Solve Fshd is spiking on competitors!
Click to see if Solve Fshd had a recent Job posting/layoffs
Solve Fshd, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Solve Fshd has new funding data
Product Launch: Get notified when Solve Fshd launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Solve Fshd
Check if Solve Fshd has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Solve Fshd
Find more new buyers
Compare Similar Companies to Solve Fshd
Compare insights from companies similar to Solve Fshd, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Solve Fshd is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
Solve Fshd is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about Solve Fshd.
Solve Fshd Tech Stack
A closer look at the technologies used by Solve Fshd
See more technologies
Solve Fshd News & Media
RESTEM Announces First-Patient-Dosed in the Phase 1/2a Study of Restem-L in Facioscapulohumeral Muscular Dystrophy
− First patient with facioscapulohumeral muscular dystrophy (FSHD) dosed with Restem-L umbilical lining modified progenitor cells (UMPCs)SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--SOLVE FSHD and Modalis partner to develop a CRISPR-based epigenome editing therapy for facioscapulohumeral muscular dystrophy (FSHD).Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.
TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its proprietary CRISPR-GNDM® epigenome editing technology, announced its recognition as a top eight finalist in the prestigious XPRIZE Healthspan competition’s FSHD Bonus Prize and award of $250,000 for demonstrating a feasible solution to treat Facioscapulohumeral muscular dystrophy (FSHD$101M XPRIZE HEALTHSPAN AWARDS FIRST MILESTONE WINNERS DRIVING TOWARD REVOLUTIONARY HEALTHY AGING ADVANCES
Over 600 competing teams from 58 countries entered global competition. Teams with a broad range of potential solutions for healthspan extension awarded in first round. NEW YORK, May 12, 2025 /PRNewswire/ -- XPRIZE, the world's leader in designing and operating large-scale incentive...
Read more news
Top Non-Profit & Charitable Organizations Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Solve Fshd
Sign Up For FreeTo access detailed company insights
SOLVE FSHD is a venture philanthropic organization dedicated to finding a cure for facioscapulohumeral muscular dystrophy (FSHD) by December 31, 2027. With a commitment of $100 million from the Wilson family, the organization aims to catalyze innovation and accelerate the development of novel therapies by partnering with leading academic, biotech,... Read More
